Literature DB >> 19344197

Murine high specificity/sensitivity competitive europium insulin autoantibody assay.

Naru Babaya1, Edwin Liu, Dongmei Miao, Marcella Li, Liping Yu, George S Eisenbarth.   

Abstract

BACKGROUND: Most insulin autoantibody assays for both human and animal models are in a radioassay format utilizing (125)I-insulin, but despite the radioassay format international workshops have documented difficulty in standardization between laboratories. There is thus a need for simpler assay formats that do not utilize radioactivity, yet retain the high specificity and sensitivity of radioassays.
METHODS: To establish an easier enzyme-linked immunosorbent assay (ELISA) for insulin autoantibodies of non-obese diabetic (NOD) mice, we used an ELISA format, competition with unlabeled insulin, europium-avidin, and time-resolved fluorescence detection (competitive europium insulin autoantibody assay).
RESULTS: The competitive europium assay of insulin autoantibodies when applied to sera from NOD mice had high sensitivity and specificity (92% sensitivity, 100% specificity) compared to our standard insulin autoantibody radioassay (72% sensitivity, 100% specificity) in analyzing blind workshop sera. It is noteworthy that though the assay has extremely high sensitivity for murine insulin autoantibodies and utilizes human insulin as target autoantigen, human sera with high levels of insulin autoantibodies are not detected.
CONCLUSIONS: Our results clearly indicate that low levels of insulin autoantibodies can be detected in an ELISA-like format. Combining a europium-based ELISA with competition with fluid-phase autoantigen can be applicable to many autoantigens to achieve high specificity and sensitivity in an ELISA format.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19344197      PMCID: PMC2903340          DOI: 10.1089/dia.2008.0072

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  20 in total

1.  The Fourth International Workshop on the Standardisation of Insulin Autoantibody Workshop.

Authors:  B Kuglin; H Kolb; C Greenbaum; N K Maclaren; A Lernmark; J P Palmer
Journal:  Diabetologia       Date:  1990-10       Impact factor: 10.122

2.  The second International Workshop on the Standardisation of Insulin Autoantibody (IAA) measurement. Held in New York, 27-30 October 1987.

Authors:  T Wilkin; J Palmer; A Kurtz; E Bonifacio; J L Diaz
Journal:  Diabetologia       Date:  1988-07       Impact factor: 10.122

3.  Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement.

Authors:  C J Greenbaum; J P Palmer; B Kuglin; H Kolb
Journal:  J Clin Endocrinol Metab       Date:  1992-05       Impact factor: 5.958

4.  Diabetes Antibody Standardization Program: first assay proficiency evaluation.

Authors:  Polly J Bingley; Ezio Bonifacio; Patricia W Mueller
Journal:  Diabetes       Date:  2003-05       Impact factor: 9.461

5.  Characterization of insulin autoantibodies in relatives of patients with type I diabetes.

Authors:  L Castaño; A G Ziegler; R Ziegler; S Shoelson; G S Eisenbarth
Journal:  Diabetes       Date:  1993-08       Impact factor: 9.461

6.  Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes.

Authors:  Peter Achenbach; Kerstin Koczwara; Annette Knopff; Heike Naserke; Anette-G Ziegler; Ezio Bonifacio
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

7.  The second murine autoantibody workshop: remarkable interlaboratory concordance for radiobinding assays to identify insulin autoantibodies in nonobese diabetic mice.

Authors:  Liping Yu; George Eisenbarth; Ezio Bonifacio; James Thomas; Mark Atkinson; Clive Wasserfall
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

8.  Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes.

Authors:  Elmar Jaeckel; Myra A Lipes; Harald von Boehmer
Journal:  Nat Immunol       Date:  2004-09-19       Impact factor: 25.606

9.  Detection of autoantibodies to protein tyrosine phosphatase-like protein IA-2 with a novel time-resolved fluorimetric assay.

Authors:  Annette Westerlund-Karlsson; Katriina Suonpää; Matti Ankelo; Jorma Ilonen; Mikael Knip; Ari E Hinkkanen
Journal:  Clin Chem       Date:  2003-06       Impact factor: 8.327

10.  Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice.

Authors:  Karine Thébault-Baumont; Danielle Dubois-Laforgue; Patricia Krief; Jean-Paul Briand; Philippe Halbout; Karine Vallon-Geoffroy; Joëlle Morin; Véronique Laloux; Agnès Lehuen; Jean-Claude Carel; Jacques Jami; Sylviane Muller; Christian Boitard
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

View more
  9 in total

1.  The next big idea.

Authors:  Marian Rewers
Journal:  Diabetes Technol Ther       Date:  2013-06       Impact factor: 6.118

2.  MAS-1 adjuvant immunotherapy generates robust Th2 type and regulatory immune responses providing long-term protection from diabetes in late-stage pre-diabetic NOD mice.

Authors:  Li Zhang; Pilar Londono; Liping Yu; Stephen Grimes; Peter Blackburn; Peter Gottlieb; George S Eisenbarth
Journal:  Autoimmunity       Date:  2014-05-01       Impact factor: 2.815

3.  A miRNA181a/NFAT5 axis links impaired T cell tolerance induction with autoimmune type 1 diabetes.

Authors:  Isabelle Serr; Martin G Scherm; Adam M Zahm; Jonathan Schug; Victoria K Flynn; Markus Hippich; Stefanie Kälin; Maike Becker; Peter Achenbach; Alexei Nikolaev; Katharina Gerlach; Nicole Liebsch; Brigitta Loretz; Claus-Michael Lehr; Benedikt Kirchner; Melanie Spornraft; Bettina Haase; James Segars; Christoph Küper; Ralf Palmisano; Ari Waisman; Richard A Willis; Wan-Uk Kim; Benno Weigmann; Klaus H Kaestner; Anette-Gabriele Ziegler; Carolin Daniel
Journal:  Sci Transl Med       Date:  2018-01-03       Impact factor: 17.956

4.  Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes.

Authors:  Li Zhang; Tomasz Sosinowski; Aaron R Cox; Joseph Ray Cepeda; Nitin S Sekhar; Sean M Hartig; Dongmei Miao; Liping Yu; Massimo Pietropaolo; Howard W Davidson
Journal:  J Autoimmun       Date:  2018-08-16       Impact factor: 7.094

5.  Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model.

Authors:  V B Gibson; T Nikolic; V Q Pearce; J Demengeot; B O Roep; M Peakman
Journal:  Clin Exp Immunol       Date:  2015-09-17       Impact factor: 4.330

6.  Perinatal tolerance to proinsulin is sufficient to prevent autoimmune diabetes.

Authors:  Gaurang Jhala; Jonathan Chee; Prerak M Trivedi; Claudia Selck; Esteban N Gurzov; Kate L Graham; Helen E Thomas; Thomas Wh Kay; Balasubramanian Krishnamurthy
Journal:  JCI Insight       Date:  2016-07-07

7.  Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope.

Authors:  Carolin Daniel; Benno Weigmann; Roderick Bronson; Harald von Boehmer
Journal:  J Exp Med       Date:  2011-06-20       Impact factor: 14.307

8.  Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay.

Authors:  Liping Yu; Dongmei Miao; Laura Scrimgeour; Kelly Johnson; Marian Rewers; George S Eisenbarth
Journal:  Diabetes       Date:  2011-11-28       Impact factor: 9.461

9.  Tolerance to Proinsulin-1 Reduces Autoimmune Diabetes in NOD Mice.

Authors:  Gaurang Jhala; Claudia Selck; Jonathan Chee; Chun-Ting J Kwong; Evan G Pappas; Helen E Thomas; Thomas W H Kay; Balasubramanian Krishnamurthy
Journal:  Front Immunol       Date:  2021-03-25       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.